Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection

  • Keyvan Karkouti
    Associate Professor, Department of Anesthesia and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada, and Scientist, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Duminda N. Wijeysundera
    Assistant Professor, Department of Anesthesia and Institute of Health Policy, Management, and Evaluation, University of Toronto, and Keenan Research Centre, Li Ka Shing Knowledge Institute of Steet Michael's Hospital, Toronto, Ontario, Canada.
  • Terrence M. Yau
    Professor, Toronto General Research Institute, University Health Network, and Division of Cardiovascular Surgery, Department of Surgery, Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada.
  • Stuart A. McCluskey
    Assistant Professor.
  • Christopher T. Chan
    Associate Professor, Division of Nephrology, Department of Medicine, University Health Network, University of Toronto.
  • Pui-Yuen Wong
    Professor, Department of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto.
  • Mark A. Crowther
    Professor, Department of Medicine, Division of Hematology, McMaster University, Hamilton, Ontario, Canada.
  • Siroos Hozhabri
    Research Coordinator.
  • W. Scott Beattie
    Professor and R. Fraser Elliott Chair in Cardiac Anesthesia, Department of Anesthesia, Toronto General Hospital, University Health Network, University of Toronto.

抄録

<jats:sec> <jats:title>Introduction</jats:title> <jats:p>: Acute kidney injury (AKI) is a serious complication of cardiac surgery, and preoperative anemia and perioperative erythrocyte transfusion are important risk factors. Prophylactic erythrocyte transfusion in anemic patients may, therefore, protect against AKI.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>: In this unblinded, parallel-group, randomized pilot trial, 60 anemic patients (hemoglobin 10-12 g/dL) undergoing cardiac surgery with cardiopulmonary bypass were randomized (1:1) to prophylactic transfusion (2 units of erythrocytes transfused 1 to 2 days before surgery (n = 29) or standard of care (transfusions as indicated; n = 31). Between-group differences in severity of perioperative anemia, transfusion, and AKI (more than 25% drop in estimated glomerular filtration rate) were measured. The relationships between transfusion, iron levels, and AKI were also measured.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>: Perioperative anemia and erythrocyte transfusions were lower in the prophylactic transfusion group--median (25th, 75th percentiles) for nadir hemoglobin was 8.3 (7.9, 9.1) versus 7.6 (6.9, 8.2) g/dL (P = 0.0008) and for transfusion was 0 (0, 2) versus 2 (1, 4) units (P = 0.0002)--but between-group AKI rates were comparable (11 patients per group). In 35 patients with iron studies, perioperative transfusions were directly related to postoperative transferrin saturation (correlation coefficient 0.6; P = 0.0002), and high (more than 80%) transferrin saturation was associated with AKI (5/5 vs. 8/30; P = 0.005), implicating transfusion-related iron overload as a cause of AKI.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>: In anemic patients, prophylactic erythrocyte transfusion reduces perioperative anemia and erythrocyte transfusions, and may reduce plasma iron levels. Adequately powered studies assessing the effect of this intervention on AKI are warranted.</jats:p> </jats:sec>

収録刊行物

  • Anesthesiology

    Anesthesiology 116 (3), 613-621, 2012-03-01

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ